Studies with NB‐360, another oxazine BACE‐1/2 inhibitor, in transgenic mice have shown beneficial effects on AD‐relevant downstream markers tau and neurofilament light chain, as well as neuronal behavior restoring impaired brain connectivity (Bacioglu et al, 2016; Keskin et al, 2017; Schelle et al, 2017). Here, MAPT is linked to Alzheimer disease.